(New York Composite Electric) In the early stage of the outbreak of crown disease, the world was facing the problem of shortage of ventilator and protective equipment; now the epidemic has entered the third year, and the treatment of severe treatment can be prevented due to the shortage of supply.Essence
The New York Times pointed out that although there are more crown drugs now, the problem is that the supply of drugs that can confront Omikdon's variants is extremely limited.At present, some American hospitals have used some coronary drugs, while other hospitals have only dozens of courses.
Health officials and doctors across the United States are therefore facing difficult choices and may decide which patients can accept the treatment of possible life.In a clinic network of low -income patients in San Diego, California, about 90%of patients with crown disease qualifications are refused outside the door.
Bergdama Salian, the chief medical execution officer of Michigan, pointed out: "Existing drugs are not enough to cope with the needs of patients who are infected in the next few weeks and face the risk of serious complications."
Before the appearance of Omikon, monoclonal antibodies were the main options for the treatment of crown disease, but the two most commonly used antibodies seemed to be invalid for Omikon.Although the third antibody drugs developed by GlaxoSmiths can effectively fight Omikon, the US government only ordered about 450,000 courses, of which many of them have been used or have not been assigned to each state.
Two weeks ago, the US Food and Drug Administration (FDA) also approved Paxlovid, Pfizer's crown disease oral medication. This drug can be taken at home and can fight against Omiko strains.
However, this drug is also in short supply in the United States. Among them, the 1,300 courses received by New York City at the end of last year were used up in just one week.The U.S. government purchased 10 million courses of PAXLOVID this Tuesday to increase the total order volume to 20 million.
